Effect of treatment with L-dopa/carbidopa or L-selegiline on striatal dopamine transporter SPECT imaging with [123I]β-CIT

Movement Disorders

Volumn 14, Issue 3, 1999, Pages 436-442

  Innis, Robert B ^a   Marek, Kenneth L ^c   Sheff, Kim ^a   Zoghbi, Sami ^c   Castronuovo, Joseph ^b   Feigin, Andrew ^b   Seibyl, John P ^c  

^a VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^b NORTH SHORE UNIVERSITY HOSPITAL   (United States)

^c VA Connecticut/116A2 ^*

Author keywords

Dopamine transporter; Parkinson's disease; SPECT

Indexed keywords

2BETA CARBOXYMETHOXY 3BETA (4 IODOPHENYL)TROPANE; CARBIDOPA; DOPAMINE TRANSPORTER; IODINE 123; LEVODOPA; SELEGILINE; TRACER; TROPANE DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CORPUS STRIATUM; DRUG BINDING SITE; DRUG EFFICACY; FEMALE; HUMAN; MALE; PARKINSON DISEASE; PRIORITY JOURNAL; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

AGED; ANTIPARKINSON AGENTS; BIOLOGICAL TRANSPORT; CARBIDOPA; COCAINE; CORPUS STRIATUM; DOPAMINE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IODINE RADIOISOTOPES; LEVODOPA; MALE; MONOAMINE OXIDASE; OCCIPITAL LOBE; PARKINSON DISEASE; SELEGILINE; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TREATMENT OUTCOME;

EID: 0033408426     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/1531-8257(199905)14:3<436::AID-MDS1008>3.0.CO;2-J     Document Type: Article

References (29)

1. Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F. Brain dopamine and the syndromes of Parkinson and Huntington: clinical, morphological, and neurochemical correlations. J Neurol Sci 1973;20:415-455.
2. Kish SJ, Shannak K, Hornykiewicz O. Uneven pattern of dopamine loss in the stratum of patients with idiopathic Parkinson's disease. N Engl J Med 1988;318:876-880.
3. Kaufman MJ, Madras BK. Severe depletion of cocaine recognition sites associated with the dopamine transporter in Parkinson's diseased striatum. Synapse 1991;9:43-49.
4. Calne DB, Langston JW, Martin WRW, et al. PET after MPTP: observations relating to the cause of Parkinson's disease. Nature 1985;317:246-248.
5. Leenders KL, Salmon EP, Tyrrell P, et al. The nigrostriatal dopaminergic system assessed in vivo by PET in healthy volunteer subjects and patients with Parkinson's disease. Arch Neurol 1990; 47:1290-1298.
6. Brooks DJ. Functional imaging in relation to parkinsonian syndromes. J Neurol Sci 1993;115:1-17.
7. Rudnick G, Clark J. From synapse to vesicle: the reuptake and storage of biogenic amine neurotransmitters. Biochim Biophys Acta 1993;1144:249-263.
8. Frost JJ, Rosier AJ, Reich SG, et al. Positron emission tomographic imaging of the dopamine transporter with C-11-Win 35,428 reveals marked declines in mild Parkinson's disease. Ann Neurol 1993;34:423-431.
9. Asenbaum S, Brücke T, Pirker W, et al. Imaging of dopamine transporters with iodine-123-β-CIT and SPECT in Parkinson's disease. J Nucl Med 1997;38:1-6.
10. Innis RB, Seibyl JP, Scanley BE, et al. Single photon emission computed tomographic imaging demonstrates loss of striatal dopamine transporters in Parkinson's disease. Proc Natl Acad Sci USA 1993;90:11965-11969.
11. 123I]β-CIT SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson's diseases. Neurology 1996;46:231-237.
12. 123I]β-CIT: pharmacological characterization of brain uptake in nonhuman primates. Synapse 1993;13:295-309.
13. Bredberg E, Tedroff J, Aquilonius SM, Paalzow L. Pharmacokinetics and effects of levodopa in advanced Parkinson's disease. Eur J Clin Pharmacol 1990;39:358-389.
14. 123I]β-CIT) in nonhuman primates: pharmacokinetics, biodistribution, and SPECT brain imaging coregistered with MRI. Nucl Med Biol 1993;20:597-606.
15. Hoehn MM, Yahr MD. Parkinsonism: onset, progression, and mortality. Neurology 1967;17:427-442.
16. Fahn S, Elton R, members of the UPDRS Development Committee. Unified Parkinson's disease rating scale. In: Fahn S, Marsden C, Calne D, Goldstein M, eds. Recent Developments in Parkinson's Disease, vol 2. Florham Park, NJ: MacMillan Healthcare Information, 1987:153-164.
17. Chang LT. A method for attenuation correction in radionuclide computed tomography. IEEE Trans Nucl Sci 1978;25:638-643.
18. 123I]β-CIT binding to dopamine transporters in healthy human subjects. J Cereb Blood Flow Metab 1994;14:982-994.
19. 123I]β-CIT SPECT. J Nucl Med 1995;36:1175-1181.
20. 123I]β-CIT striatal uptake correlates with symptom severity in idiopathic Parkinson's disease. Ann Neurol 1995;38:589-598.
21. 123I]β-CIT SPECT brain measurement of dopamine transporters in Parkinson's disease. J Nucl Med 1997;38:1453-1458.
22. Diggle P, Kung-yee L, Zeger S. Analysis of Longitudinal Data. New York, NY: Oxford Science Publications, 1994.
23. Vander Borght T, Kilbourn M, Desmond T, Kuhl D, Frey K. The vesicular monoamine transporter is not regulated by dopaminergic drug treatments. Eur J Pharmacol 1995;294:577-583.
24. Reynolds GP, Riederer P, Sandler M, Jellinger K, Seeman P. Amphetamine and 2-phenylethylamine in post-mortem parkinsonian brain after (-)-deprenyl administration. J Neurol Transm 1978;43: 271-277.
25. 3H]cocaine binding associated with dopamine uptake sites in the rat striatum and human putamen decrease after dopaminergic denervation and in Parkinson's disease. Naunyn Schmiedeberg's Arch Pharmacol 1985;329:227-235.
26. Fang J, Yu PH. Effect of L-deprenyl, its structural analogues and some monoamine oxidase inhibitors on dopamine uptake. Neuropharmacology 1994;33:763-768.
27. Niznik HB, Fogel EF, Fassos FF, Seeman P. The dopamine transporter is absent in parkinsonian putamen and reduced in the caudate nucleus. J Neurochem 1991;56:192-198.
28. 123I]IBZM for SPECT imaging of human brain dopamine receptors: occupancy by the novel antipsychotic RWJ-37796. J Nucl Med 1996;37:11-15.
29. 123I]β-CIT SPECT brain measurement of dopamine transporters in healthy human subjects. J Nucl Med 1996;37:222-227.